GLP1 Weight Loss Drugs Linked To Rare Brain Disorder Cases

Popular weight-loss medications including Ozempic, Wegovy, Mounjaro and Zepbound have transformed the way millions of people approach obesity and diabetes treatment. Now, a new study has identified a small number of patients taking these drugs who developed a rare neurological disorder associated with severe vitamin B1 deficiency.

The researchers identified 15 reported cases of Wernicke encephalopathy among people taking GLP-1 receptor agonists. The condition can cause confusion, balance problems, abnormal eye movements and permanent neurological damage when it is left untreated.

The findings do not prove that GLP-1 medications caused the disorder. However, researchers and clinicians say the reports raise concerns about what can happen when powerful appetite suppression is combined with vomiting, poor food intake and rapid weight loss.

Researchers Found 15 Cases Of A Rare Brain Condition

The study, published in Clinical Nutrition, examined cases of Wernicke encephalopathy reported among people taking GLP-1 medications. Researchers drew information from the U.S. Food and Drug Administration’s Adverse Event Reporting System, published medical literature and their own medical center.

The cases occurred during 2023 and 2024 and involved medications containing semaglutide or tirzepatide. Semaglutide is the active ingredient in Ozempic and Wegovy, while tirzepatide is used in Mounjaro and Zepbound.

Wernicke encephalopathy is caused by a severe deficiency of thiamine, also known as vitamin B1. This vitamin is required for normal brain and nerve function, making a prolonged deficiency potentially dangerous.

The number of reported cases is extremely small compared with the number of people using these medications. Karthik Achari, a Chicago-based clinician who was not involved in the research, emphasized that distinction when discussing the findings with Fox News Digital.

“Researchers went through adverse event reports and the medical literature and found a small number of cases, 15, of Wernicke encephalopathy in people taking GLP-1 drugs,” Achari told Fox News Digital. “That’s out of millions of people on these medications. So this is rare.”

The finding nevertheless deserves attention because the reported patients shared several nutritional and gastrointestinal problems that could potentially contribute to vitamin B1 deficiency.

Most Patients Had Serious Nutrition Or Digestive Problems

The researchers found that 13 of the 15 patients reported gastrointestinal or nutritional problems. These included vomiting, loss of appetite, weight loss and malnutrition.

That pattern provides an important piece of context for understanding the study. The concern is not simply that someone takes a GLP-1 medication and suddenly develops a vitamin deficiency. Rather, appetite suppression and gastrointestinal symptoms may make it difficult for some patients to consume and retain enough food to meet their nutritional needs.

GLP-1 medications can reduce appetite and increase feelings of fullness. For someone trying to lose weight, that effect is part of how the medications can reduce overall food intake. The same effect can become concerning when a person’s intake falls too far or when persistent vomiting prevents adequate nutrition.

Achari described the problem in particularly direct terms when speaking to Fox News Digital.

“But it’s real, it’s serious, and the mechanism makes sense,” he said.

He explained that reducing appetite does not reduce the body’s requirement for essential nutrients. “The drug shrinks your appetite. It doesn’t shrink your body’s requirements,” Achari said.

That distinction becomes particularly relevant for people who are eating very little while also experiencing repeated vomiting or other gastrointestinal symptoms.

Why Vitamin B1 Is So Important

Thiamine is essential for normal neurological function, and severe deficiency can affect the brain and nervous system. When the deficiency becomes serious enough, Wernicke encephalopathy can develop.

According to the supplied research reports, people with the condition may experience confusion, difficulty walking, balance problems and changes involving the eyes. Without treatment, neurological damage can become permanent.

Memory can also be affected. The condition can lead to permanent memory loss and an inability to form new memories, making early recognition particularly important.

Vitamin B1 is obtained through food and supplements. Foods identified in the supplied reports as sources include pork, fish and whole grains.

When someone has a dramatically reduced appetite, however, consuming a varied diet can become more difficult. Persistent vomiting can make the situation even more serious because food and fluids may not remain in the body long enough to provide adequate nutrition and hydration.

The Symptoms Can Look Like Ordinary Medication Side Effects

One of the difficulties surrounding nutritional deficiencies is that early symptoms can overlap with symptoms people already associate with weight-loss medications.

Nausea, poor appetite and fatigue may be dismissed as expected side effects. Someone experiencing those symptoms may therefore assume that nothing unusual is happening, particularly during the early stages of treatment or after a dosage change.

Clare Collins, laureate professor of nutrition and dietetics at The University of Newcastle in Australia, raised a similar concern when discussing nutritional deficiencies associated with appetite-suppressing medications.

“The signs can be missed because they overlap initially with side effects of the medications, including fatigue, lethargy, nausea, poor appetite and irritability,” Collins said.

That overlap means persistent symptoms should not automatically be brushed aside.

Erin Palinski-Wade, a New Jersey-based nutritionist and author, also warned against treating severe symptoms as something patients simply have to tolerate while taking a GLP-1 medication.

“Don’t assume every side effect is just part of being on a GLP-1,” Palinski-Wade told Fox News Digital. “Severe or persistent symptoms deserve attention.”

The supplied reports specifically point to ongoing vomiting and diarrhea as concerns because those symptoms can contribute to dehydration and other complications.

Some GLP-1 Users May Face Greater Nutritional Risk

The study does not establish that particular categories of GLP-1 users will develop Wernicke encephalopathy. It does, however, identify circumstances that clinicians believe can make severe nutritional deficiency more concerning.

Achari said people with persistent nausea and vomiting, those losing weight very quickly while eating very little, people with a history of bariatric surgery and people who use alcohol heavily may face greater risk of vitamin B1 deficiency.

Those circumstances can affect nutritional status for different reasons. Someone who is barely eating may struggle to obtain enough thiamine from food. Repeated vomiting can further interfere with food and fluid intake, while previous bariatric surgery can be associated with nutritional challenges.

Heavy alcohol use is another established concern in the context of thiamine deficiency.

None of these factors means that a person will develop Wernicke encephalopathy. They instead help explain why nutritional monitoring may deserve more attention when food intake becomes very low.

Rapid Weight Loss Does Not Guarantee Good Nutrition

The broader concern extends beyond vitamin B1. A person can lose weight while still failing to consume enough essential nutrients.

Collins said the issue has not received enough attention in clinical research involving diabetes and obesity medications. A systematic review by the Hunter Medical Research Institute in Australia found that clinical trials have often failed to adequately report what people actually eat while taking these medications.

“A reduction in body weight does not automatically mean the person is well-nourished or healthy,” Collins wrote in a press release statement.

She said the strong effects of some GLP-1 and GIP medications on appetite and satiety can reduce overall food intake. If diet quality and nutritional adequacy are not monitored, people may consume inadequate amounts of protein, fiber, vitamins and minerals.

That concern puts the new Wernicke encephalopathy reports into a wider nutritional context. The rare brain condition is one potential consequence of severe deficiency, but inadequate intake can affect many parts of the body.

The Warning Also Extends To Other Vitamin Deficiencies

The concern around GLP-1 medications and nutrition is not limited to thiamine.

Reference material supplied for this story also points to reports about scurvy, a condition caused by severe vitamin C deficiency. Scurvy became known historically as a “pirate disease” because sailors on long voyages could lack access to fresh foods.

Severe vitamin C deficiency can cause symptoms including anemia, bruising, bleeding beneath the skin, swollen or bleeding gums, loose teeth, rough skin and poor wound healing. These symptoms can become serious when the underlying deficiency is left untreated.

Australian researchers have raised concerns that reduced food intake among people using appetite-suppressing medications could increase the risk of several nutrient deficiencies if diet quality is not maintained.

Collins emphasized that scurvy represents only one possible deficiency problem. Other nutrients can also become inadequate when someone consistently consumes too little food or has a highly restricted diet.

Iron deficiency, for example, can contribute to anemia. Severe vitamin B1 deficiency can contribute to beriberi, which can damage the nerves and heart, as well as Wernicke encephalopathy.

The central issue is therefore broader than one rare neurological diagnosis. Reduced appetite can make it harder for some people to obtain the range of nutrients their bodies require.

What A Nutritionist Says GLP-1 Users Should Watch

Palinski-Wade said people taking GLP-1 medications need to pay attention to nutrition even when their appetite is substantially reduced.

“GLP-1 medications can dramatically reduce appetite, but that also means people may unintentionally under-eat the very things their bodies need most, especially protein, fiber and fluids,” she told Fox News Digital.

Her comments point to a practical challenge facing people using appetite-suppressing medications. Eating less can be expected, but eating so little that nutritional needs are consistently missed presents a different problem.

The supplied reports also note that ongoing vomiting or diarrhea can increase the risk of dehydration and kidney problems. Palinski-Wade recommended seeking medical guidance when those symptoms persist for roughly 24 hours.

People experiencing concerning symptoms can discuss their food intake and nutritional status with a qualified healthcare professional or dietitian. Collins specifically recommended seeking professional help from an accredited dietitian because assessing nutrient intake accurately can be difficult without guidance.

She said some people may require nutritional support, potentially including a multivitamin or mineral supplement and medical nutrition therapy. Those decisions should be individualized rather than treated as a universal requirement for everyone taking a GLP-1 medication.

Warning Signs That Should Not Be Ignored

The reports identify several symptoms and circumstances that deserve attention when they occur alongside substantial appetite suppression or rapid weight loss:

• Persistent vomiting or diarrhea: Continued gastrointestinal symptoms can make it difficult to maintain adequate food and fluid intake.
• Very low food intake: A dramatically reduced appetite can make it harder to obtain enough protein, vitamins and minerals.
• Rapid weight loss: Losing weight quickly while consuming very little can increase concern about nutritional adequacy.
• Neurological symptoms: Confusion, problems with balance, difficulty walking or unusual eye movements can occur with Wernicke encephalopathy.
• Ongoing fatigue or weakness: These symptoms can have many causes, but they can also overlap with nutritional deficiencies and should be discussed when persistent.

These symptoms do not automatically mean someone has a vitamin deficiency or Wernicke encephalopathy. They are included because the supplied reports describe them as relevant warning signs or risk factors that may warrant medical attention.

The Study Does Not Prove GLP-1 Drugs Caused The Disorder

The most important limitation of the research is also one of the easiest details to lose in a dramatic headline.

The study identified cases occurring among people who were taking GLP-1 medications, but the researchers could not establish that the drugs themselves caused Wernicke encephalopathy.

The FDA’s adverse-event reporting system can help researchers identify potential safety signals. Reports in such databases cannot independently establish causation because patients may have other medical conditions, medications, nutritional problems or circumstances that contribute to an adverse event.

The researchers acknowledged this limitation and called for additional research.

The small number of cases also needs to be considered alongside the large number of people using these medications. Achari stressed that 15 cases represent a rare occurrence among millions of users.

The findings therefore should not be interpreted as evidence that GLP-1 medications commonly cause Wernicke encephalopathy.

At the same time, the rarity of a condition does not make its symptoms irrelevant. Wernicke encephalopathy can become life-threatening when severe thiamine deficiency is not treated, which is why clinicians emphasize early recognition.

Researchers Want Clinical Trials To Track Nutrition More Closely

The new study has also opened a broader question about how nutritional health is measured during medical weight loss.

Collins argued that clinical trials should provide better information about what participants actually consume while using appetite-suppressing medications. She called for future studies to use validated dietary assessment tools and transparent reporting of food and nutrient intake.

Better nutritional data could help researchers determine how often deficiencies occur and identify which patients are most vulnerable.

That information could also help clinicians develop clearer strategies for monitoring patients whose appetite falls sharply.

The researchers behind the Wernicke encephalopathy study similarly called for additional research. Their findings provide a potential safety signal, but they do not answer every question about why the cases occurred or how frequently comparable problems may exist among the wider GLP-1 population.

For now, the evidence supports caution around severe nutritional deprivation rather than fear of the medications themselves.

Patients Should Not Stop Prescribed Medication Based On This Study

The experts quoted in the supplied reports stressed that patients should not stop taking prescribed GLP-1 medications solely because of these findings.

Instead, the issue is whether people experiencing significant side effects are receiving enough nutritional support and medical attention.

GLP-1 medications are designed to reduce appetite and food intake, but the body still needs essential nutrients even when hunger decreases. Persistent vomiting, extremely low food intake or neurological symptoms can signal a problem that deserves professional assessment.

The distinction is especially important because many common medication side effects can overlap with symptoms of nutritional deficiencies.

The study has not established that GLP-1 medications directly cause Wernicke encephalopathy. It has identified 15 cases that researchers believe warrant further investigation, particularly because many patients also experienced vomiting, appetite loss, rapid weight loss or malnutrition.

For people using these medications, the practical message is straightforward: weight loss should not come at the expense of adequate nutrition. When severe symptoms make eating or drinking difficult, treating them as routine side effects could allow a serious deficiency to go unnoticed.